AI giants are planning up to US$828b in data center and chip spending this year, and that level of capital tied up in one corner of the market has many investors rethinking concentration risk. Capital that chases one story often overlooks steadier essentials like healthcare. This piece looks at three leading healthcare stocks from a curated screen of financially solid operators and explains why they may warrant a closer look now.
The three stocks that follow are just a small sample, and the full screen surfaced 33 more healthcare companies with equally compelling stories that are not covered here. To size up that wider opportunity set and identify your own high-conviction ideas, go straight to the Best Healthcare Stocks screener .
GeneDx Holdings (WGS)
Overview:GeneDx Holdings provides whole exome and whole genome sequencing and AI supported clinical genetic testing that helps doctors diagnose pediatric, rare disease, hereditary risk, and cancer cases.
Operations:GeneDx generated about US$454 million of revenue, with US$423 million from its core segment adjustment and roughly US$31 million from Fabric Genomics and Legacy Sema4, almost entirely in the United States.
Market Cap:US$2.1 billion
GeneDx Holdings matters for this healthcare screen because it brings hospital grade genetic testing and AI based interpretation directly into routine clinical decision making.
"While management is prioritizing payer coverage and AI driven revenue cycle tools to close the gap between current collection rates around the low 30% range and the longer term ~70% target, the persistence of roughly 32% outpatient genome collections through Q2 2026 suggests that any improvement in net collections and earnings could arrive more slowly than the volume growth in tests."
The real swing factor for GeneDx Holdings is what happens if a single pressure point quietly reshapes how much profit each test can actually retain.
That pressure point is exactly what the full narrative for GeneDx Holdings unpacks, including how payer behavior and AI tools could decouple test volumes from future earnings power.
Axogen (AXGN)
Overview:Axogen focuses on peripheral nerve regeneration by supplying grafts and implants like Avance Nerve Graft and Axoguard products to surgeons worldwide.
Market Cap:US$3 billion
Axogen matters in the Best Healthcare Stocks screen because its Avance Nerve Graft and Axoguard or Avive soft-tissue repair line are already used in real-world surgeries, giving the business tangible, procedure-linked revenue in a very specific corner of medical devices.
"Upcoming FDA Biologics License Application (BLA) approval for Avance Nerve Graft in September 2025 is expected to secure 12 years of market exclusivity and establish Avance as the only biologic with this indication, which should drive pricing power, limit biosimilar competition, and boost both gross margin and long-term earnings visibility."
What happens if the one factor that shapes surgeon loyalty and payer support starts to shift at the same time as that exclusivity window?
If that shift is on your radar, the full narrative for Axogen outlines how Axogen's exclusivity, surgeon behavior and payer decisions could accelerate or stall the story from here.
ADMA Biologics (ADMA)
Overview:ADMA Biologics develops and sells plasma-derived immunoglobulin therapies like BIVIGAM and ASCENIV that help treat immune deficiencies and infectious diseases.
Operations:ADMA Biologics generated about US$495 million from ADMA Biomanufacturing and US$17 million from Plasma Collection Centers, with roughly US$508 million in sales coming from the United States.
Market Cap:US$2.6 billion
For a healthcare screen focused on real-world treatment exposure, ADMA Biologics matters because its IVIG therapies directly support physicians managing complex immune disorders in hospitals and infusion centers.
"Rapidly increasing adoption and utilization of ASCENIV is being reinforced by real world data in 127 medically complex primary immunodeficiency patients and a May 2026 FDA label expansion into children aged 2 years and older. This broadens the addressable pool of patients and supports revenue growth and mix driven margin expansion."
What happens if a single tension between product mix and competitive pricing quietly dictates how much of that treatment demand turns into durable margins?
That margin question is exactly what the full narrative for ADMA Biologics tackles, explaining how ADMA Biologics could translate ASCENIV traction into accelerating, more durable earnings power.
Seeking Fresh Alternatives Beyond Healthcare?
Fresh ideas move first. Stocks with quiet momentum often get caught flying higher before most investors even notice. Scan under the radar for now and act now.
-
Spot potential trend leaders before momentum headlines hit by running the 18 high quality undiscovered gems while the stories are still underfollowed and expectations have not fully caught up.
-
Target steadier compounding potential by working through the list of solid balance sheet and fundamentals (25 results) so you focus on businesses with cleaner finances and fewer balance sheet surprises.
-
Ride structural demand shifts by reviewing the 39 power grid technology and infrastructure stocks and track companies plugged into long-term upgrades in energy infrastructure and grid technology.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
